Aratana Therapeutics Inc. (NASDAQ:PETX) and Neptune Wellness Solutions Inc. (NASDAQ:NEPT), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aratana Therapeutics Inc.	35.41M	4.98	14.72M	-0.51	0.00
Neptune Wellness Solutions Inc.	N/A	0.00	N/A	-0.07	0.00

In table 1 we can see Aratana Therapeutics Inc. and Neptune Wellness Solutions Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Aratana Therapeutics Inc. and Neptune Wellness Solutions Inc.?s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aratana Therapeutics Inc.	-41.57%	-23%	-16.1%
Neptune Wellness Solutions Inc.	0.00%	0%	0%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Aratana Therapeutics Inc. and Neptune Wellness Solutions Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Aratana Therapeutics Inc.	0	2	2	2.50
Neptune Wellness Solutions Inc.	0	0	0	0.00

Aratana Therapeutics Inc. has a 85.28% upside potential and a consensus target price of $6.67.

Insider and Institutional Ownership

Roughly 69.1% of Aratana Therapeutics Inc. shares are owned by institutional investors while 17.69% of Neptune Wellness Solutions Inc. are owned by institutional investors. Aratana Therapeutics Inc.’s share owned by insiders are 2.5%. Competitively, insiders own roughly 23.43% of Neptune Wellness Solutions Inc.?s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aratana Therapeutics Inc.	-3.6%	-9.26%	-39.09%	-23.43%	3.08%	-34.42%
Neptune Wellness Solutions Inc.	-4.63%	3.86%	8.36%	-14.63%	43.44%	37.8%

For the past year Aratana Therapeutics Inc. had bearish trend while Neptune Wellness Solutions Inc. had bullish trend.

Summary

On 6 of the 10 factors Neptune Wellness Solutions Inc. beats Aratana Therapeutics Inc.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the company’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through oceano3.com in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.